Takeda Pharmaceutical Company

October 9, 2017

Adcetris Induced Durable, Long-term Remission in Nearly Half of Large Cell Lymphoma Patients in Phase 2 Trial

News

More than half of patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL, a particularly aggressive type of lymphoma) who received Adcetris (brentuximab vedotin) during a pivotal Phase 2 ... Read more

June 29, 2017June 29, 2017

Adcetris-Chemotherapy Combo Lengthens the Time for Hodgkin’s Lymphoma to Progress, Trial Shows

News

Adding Adcetris (brentuximab vedotin) to standard chemotherapy significantly lengthens the time it takes for Hodgkin’s lymphoma to progress, or for a patient to die, according to an updated of Phase 3 clinical ... Read more

June 13, 2017June 13, 2017

Adcetris Shows Promise in Phase 3 Trial to Treat Certain Cutaneous T-Cell Lymphoma Patients

News

The investigational therapy Adcetris (brentuximab vedotin) shows promise as a potential treatment for patients with cutaneous T-cell lymphoma (CTCL), according to results of a Phase 3 clinical trial. Findings were published in ... Read more

August 3, 2016April 4, 2017

Adcetris Shows Promise in Treating Cutaneous T-Cell Lymphoma in Phase 3 Study

News

Adcetris may greatly benefit patients with cutaneous T-cell lymphoma (CTLC) who received prior systemic or radiation therapy, according to Phase 3 clinical trial results recently announced by Takeda Pharmaceutical Company and Seattle Genetics. The study met ... Read more

July 7, 2016July 7, 2016

European Commission Approves Adcetris as Consolidation Treatment for Post-transplant Hodgkin’s Lymphoma Patients

News

The European Commission has approved Adcetris (brentuximab vedotin) for the treatment of adults with CD30-positive Hodgkin’s lymphoma at increased risk of relapse or progression after autologous stem cell transplant (ASCT), ... Read more